4.21
Zura Bio Ltd stock is traded at $4.21, with a volume of 489.71K.
It is down -3.44% in the last 24 hours and down -21.75% over the past month.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
See More
Previous Close:
$4.36
Open:
$4.4
24h Volume:
489.71K
Relative Volume:
0.76
Market Cap:
$399.45M
Revenue:
-
Net Income/Loss:
$-75.43M
P/E Ratio:
-3.4505
EPS:
-1.2201
Net Cash Flow:
$-72.75M
1W Performance:
+5.51%
1M Performance:
-21.75%
6M Performance:
+10.79%
1Y Performance:
+312.75%
Zura Bio Ltd Stock (ZURA) Company Profile
Name
Zura Bio Ltd
Sector
Industry
Phone
858-247-0520
Address
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ZURA
Zura Bio Ltd
|
4.21 | 413.68M | 0 | -75.43M | -72.75M | -1.2201 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Initiated | Wedbush | Outperform |
| Nov-04-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| May-03-24 | Initiated | Piper Sandler | Overweight |
| Oct-10-23 | Initiated | Ladenburg Thalmann | Buy |
| Aug-25-23 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Guggenheim | Buy |
| Jun-14-23 | Initiated | Chardan Capital Markets | Buy |
| May-24-23 | Initiated | Raymond James | Strong Buy |
View All
Zura Bio Ltd Stock (ZURA) Latest News
Zura Bio (NASDAQ: ZURA) discloses resignation of director Someit Sidhu - Stock Titan
Zura Bio Ltd stock (KYG989201089): pipeline update keeps autoimmune story in focus - AD HOC NEWS
Venrock entities report 9.99% ownership in ZURA (ZURA) - Stock Titan
Great Point Partners, Dr. Jay & Nordahl report 4.44% in ZURA (ZURA) - Stock Titan
Zura Bio reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zura Bio stock (KYG989201089): Appoints Muzammil Mustufa as Chief Business Officer - AD HOC NEWS
Zura Bio's new CBO gets options on 600,000 shares at $4.80 - Stock Titan
Zura Bio appoints Muzammil Mustufa as chief business officer By Investing.com - Investing.com Canada
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer - ChartMill
TradingKey - TradingKey
Suvretta/Averill disclose large ZURA stakes (NASDAQ: ZURA) in 13G/A filing - Stock Titan
Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Insider Purchases Worth US$12.5m See Losses As Zura Bio Market Value Drops To US$464m - simplywall.st
Zura Bio Ltd 1Q 2026: Net income $(24.2M), EPS $(0.22) — 10-Q Summary - TradingView
Zura Bio (Nasdaq: ZURA) widens Q1 loss, boosts cash to $225.6M - Stock Titan
Zura Bio (NASDAQ: ZURA) boosts cash with $134.6M raise as R&D loss deepens - Stock Titan
Zura Bio Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates - ChartMill
Zura says it has enough cash to operate through 2028 as two trials advance - Stock Titan
JPMorgan reports 4.47M Zura Bio holdings (NASDAQ: ZURA) — 4.7% stake - Stock Titan
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Eight new Zura Bio hires get options tied to 615,160 shares - Stock Titan
Zura Bio | DEF 14A: Definitive information statements - Moomoo
ZURA Stock Price, Quote & Chart | ZURA BIO LTD (NASDAQ:ZURA) - ChartMill
Zura Bio | ARS: Annual Report to Security Holders - Moomoo
[ARS] Zura Bio Ltd SEC Filing - Stock Titan
[DEF 14A] Zura Bio Ltd Definitive Proxy Statement - Stock Titan
ZURA News | ZURA BIO LTD (NASDAQ:ZURA) - ChartMill
Zura Bio Limited 8-K Filing Details April 2026 – Separation Agreement, Company Information, and SEC Compliance - Minichart
Zura Bio LtdEric Hyllengren separated from Zura Bio Limited as CFO on April 20, 2026 - marketscreener.com
Zura Bio : Corporate Overview April 2026 (d9fec3) - marketscreener.com
Zura Bio Limited Announces CFO Changes, Effective April 20, 2026 - marketscreener.com
[8-K] Zura Bio Ltd Reports Material Event - Stock Titan
Jessica Chen - White & Case LLP
One Zura Bio Insider Raised Their Stake In The Previous Year - Yahoo Finance
JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering - Benzinga
JATT Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
JATT Technical Analysis & Stock Price Forecast - Intellectia AI
JATT PE Ratio & Valuation, Is JATT Overvalued - Intellectia AI
JATT Forecast — Price Prediction for 2026. Should I Buy JATT? - Intellectia AI
Zura Bio Ltd stock (KYG989201089): Is its immunology pipeline strong enough to unlock biotech upside - AD HOC NEWS
Zura Bio Ltd stock: Why analysts see massive upside potential - AD HOC NEWS
Zura Bio (NASDAQ:ZURA) Shares Down 6.5%Here's What Happened - MarketBeat
Biotechnology executive pays $15 million for Pinecrest home (Photos) - The Business Journals
Zura Bio (ZURA) CTO awarded 263,000 share options at $6.03 strike price - Stock Titan
Zura Bio (ZURA) officer receives 340,900 options at $6.03 strike price - Stock Titan
Zura Bio (ZURA) CFO receives stock options for 340,900 shares at $6.03 - Stock Titan
Zura Bio grants 425,700 options to legal chief | ZURA Insider Trading - Stock Titan
Zura Bio (ZURA) CEO awarded options on 894,000 Class A shares - Stock Titan
Chipmakers Recap: Is Zura Bio Limited a momentum stock2026 Highlights & Verified Swing Trading Watchlist - baoquankhu1.vn
Market Fear: Will Zura Bio Limited benefit from rising consumer demandChart Signals & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Zura Bio Ltd Stock (ZURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):